Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
You could win a cash prize of up to £25,000 when you play the JDRF lottery. As well as the chance to win great prizes, you'll also help fund our research to find a cure for type 1 diabetes.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join us on Saturday 21 September 2024 with hundreds of JDRF supporters celebrating One Walk Belfast!
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF is undergoing a transformation.We are becoming Breakthrough T1D in October.
Home > News & events > News > New international medical code launches for presymptomatic type 1 diabetes
A new code for presymptomatic type 1 diabetes has today been added to SNOMED CT, a standardised, international, multilingual set of clinical healthcare terminology. SNOMED codes are added to electronic health records to identify what conditions a person has. It is the most comprehensive and precise clinical health terminology system in the world.
Type 1 diabetes develops gradually, and this progression occurs in three stages, with the first two stages called presymptomatic type 1 diabetes. People with presymptomatic type 1 diabetes have biological markers of type 1 diabetes, known as autoantibodies, which show the immune attack that destroys insulin-producing beta cells has begun. As the symptoms of type 1 are not present at this stage, we rely on screening programmes such as the ELSA study, which are funded by charities like JDRF, for early detection.
Dr Lauren Quinn at the University of Birmingham, who co-leads the ELSA study and helped develop the new medical code, said: “The introduction of this SNOMED code allows researchers to identify people who could benefit from novel therapies to delay the onset of type 1 diabetes and recruit them to clinical trials of immunotherapies. This will transform type 1 diabetes research by fast-tracking recruitment, unravelling how the condition develops and progresses, and bringing us closer to licensed disease-modifying treatments in type 1 diabetes.”
Dr David Shukla, a GP and Clinical Research Fellow who helped develop the new SNOMED code, said: “The inclusion of a code for the diagnosis of presymptomatic type 1 diabetes will highlight to healthcare professionals involved in their care the individuals who are at high risk of developing type 1 diabetes. This will help ensure that when these people progress and develop symptomatic type 1 diabetes, it will be picked up and treated at a much earlier stage.
This reduces the risk of them presenting or being diagnosed late and developing diabetic ketoacidosis, an emergency complication of type 1 diabetes that can be fatal. This timely pick up and initiation of prompt treatment will lead to substantial improvements in their diabetes and future care.”
Hilary Nathan, Director of Policy and Communications at JDRF UK, said: “This recognition of presymptomatic type 1 diabetes with a SNOMED code is a crucial step towards the implementation of population screening programmes for early detection of type 1 diabetes. Early detection leads to short and long-term health benefits, improved quality of life and cost savings for healthcare providers.
The new code will unlock better monitoring, follow-up and education for people in the earliest stages of type 1. It will also help facilitate recruitment into clinical trials of emerging treatments, enabling people developing type 1 diabetes to access therapies that have the potential to claw back valuable time free from the burdens of type 1 diabetes management.”
A study we helped conduct, which has just been published, reveals the most important unanswered questions about type 1 diabetes, based on the priorities of adults in the United Kingdom and Ireland. This will help guide future research to focus on what matters most to people living with the condition.
When given to mice and pigs with type 1 diabetes, a new type of oral insulin developed with JDRF funding detects rising blood glucose and quickly lowers it to a safe level without causing hypos.
New research finds that ustekinumab, a drug commonly used to treat psoriasis, may help children and adolescents with type 1 diabetes keep making insulin for longer.
New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.
